Donald J. Hillebrand, MD

Professional Background

Liver Transplantation – optimizing patient selection.
Liver Failure – liver assist treatments for encephalopathy, hepatorenal syndrome and other complications of end-stage liver disease.
Hepatic Encephalopathy (rifaximin therapy)
Hepatocellular carcinoma development and therapies.
Ascites - ascitic fluid analysis, ascitic fluid infection (prior work with Bruce Runyon).
Hepatitis therapies (HBV and HCV).
NASH therapies.

• BS, Microbiology, Iowa State University, Ames, IA
• MD, MD, University of Iowa College of Medicine, Iowa City, IA
• Internship, Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA
• Residency, Internal Medicine, University of Iowa Hospitals and Clinics
• Clinical Fellowship, Gastroenterology-Hepatology, University of Iowa Hospitals and Clinics

• University of Kansas Medical Center, Center for Transplantation Selection Committee, Member, 2023 - Present

---

• Yates WR, Martin M, LaBrecque D, Hillebrand D, Voigt M, Pfab D. 1998. A model to examine the validity of the 6-month abstinence criterion for liver transplantation. Alcohol Clin Exp Res, 22 (2), 513-7. https://pubmed.ncbi.nlm.nih.gov/9581661/
• Hu Ke-Qin, Hillebrand Donald J, Chen CS. 2002. A Pilot Study of Celecoxib Tolerability in Patients with Chronic Liver Disease (CLD) and Stage III-IV Hepatocellular Carcinoma (HCC). Gastroenterol, M1279